Smith & Nephew SNATS Inc logo

Smith & Nephew SNATS Inc(SNN)

upturn advisory logo
EXPLORE ADVISORIES AND THEIR HISTORY
QUALITY SIGNAL RECENCY
1-STAR RATING
Consider higher Upturn Star rating
BUY for 24 days
PROFIT SINCE LAST BUY
+1.74% ▲
LAST CLOSE
$29.83
11/20/2026
(24-hour delay)

Advisory History & Simulated Performance *

*as per simulation (see disclosures)
  • ALL
  • 1Y
  • 1M
  • 1W
  • BUY Advisory
  • SELL Advisory (Profit)
  • SELL Advisory (Loss)
  • Profit
  • Loss
  • PASS (Skip)
Upturn Stock price based on last close iconStock price based on last close
Simulated performance—not actual client returns. Excludes advisory subscription fees, trading commissions, and taxes, which would reduce returns. Results depend on calculation assumptions and do not guarantee future outcomes. See Disclosures for full methodology, assumptions, and limitations.

Advisory Performance History (Simulated)Advisory Performance History info

Simulated performance—not actual client returns. Excludes advisory subscription fees, trading commissions, and taxes, which would reduce returns. Results depend on calculation assumptions and do not guarantee future outcomes. See Disclosures for full methodology, assumptions, and limitations.

Upturn Advisory & Investor View for SNN

11/20/2026: SNN (1-star) has a low Upturn Star Rating. Not recommended to BUY.

Smith & Nephew SNATS Inc is a global medical technology company specializing in orthopaedics, sports medicine, and advanced wound management. The company's primary strengths lie in its established brand reputation, sticky hospital relationships, and expanding portfolio of advanced surgical robotics like the CORI system. Its core investment story centers on capturing long-term growth driven by aging demographics and rising elective procedure volumes worldwide. However, key risks include intense competition from larger medical device giants, hospital budget constraints, and potential supply chain friction. The stock suits value-oriented and dividend-conscious healthcare investors who should monitor elective surgery recovery trends and robotics adoption metrics.

How to Read the Upturn Advisory

The Upturn Star Rating and the current BUY, SELL, or PASS advisory are generated by Upturn’s AI advisory engine based on proprietary signal analysis, price behavior, advisory history, and historical signal performance.

Company fundamentals, valuation, risks, and news provide supporting context about the business.

Investor Fit

Investor styleFitWhy
Growth investorMixed fitWhile operating in structurally growing medical markets, top-line expansion tends to be moderate compared to high-beta technology sectors.
Momentum investorStrong fit while signal remains positiveShort-term momentum is conditional on favorable earnings beats or positive sentiment shifts regarding elective surgery recoveries.
Value investorMixed fitValuation is often tied to steady healthcare demand, presenting balanced upside without deep cyclical discount characteristics.
Dividend investorStrong fitThe company offers reliable dividend distributions supported by stable cash flows from established healthcare product segments.
Low-risk investorMixed fitAlthough backed by essential healthcare demand, the stock remains subject to foreign exchange fluctuations, regulatory hurdles, and market volatility.

Risk Profile

Risk factorLevelWhy it matters
Price volatilityMediumThe stock experiences standard equity fluctuations driven by broader market sentiment and quarterly healthcare sector updates.
Valuation riskMediumValuation multiples can compress if organic revenue growth fails to meet analyst expectations.
Competition risk (Stryker and Zimmer Biomet)HighAggressive market competition from larger orthopaedic juggernauts can pressure pricing power and market share.
Business qualityStrongThe company possesses durable healthcare franchises, sticky hospital customer relationships, and globally recognized brands.
Dividend incomeMedium / highConsistent dividend payments provide a dependable income baseline for investors seeking healthcare yield.
Execution riskMedium / highSuccessful execution of supply chain overhauls and new product rollouts is critical to margin improvement.

Key Highlights

Company Size Large-Cap Stock
Market Capitalization 12.47B USD
Price to earnings Ratio 20.29
1Y Target Price 33.19
Price to earnings Ratio 20.29
1Y Target Price 33.19
Volume (30-day avg) 1.4M shares
Beta 0.67
52 Weeks Range 26.07 - 36.11
Updated Date 11/20/2026
52 Weeks Range 26.07 - 36.11
Updated Date 11/20/2026
Dividends yield (FY) 2.66%
Basic EPS (TTM) 1.47

Sector & Industry Intelligence

Sector

Healthcare

Constructive
Sentiment
Strong Bullish
Momentum
BUY Breadth Improving
BUY participation
55.2%
Active BUY / eligible
53 / 96
30-Day BUY Count Change
+19
Market state
Strong Bullish

More qualifying stocks are receiving or maintaining BUY advisories, indicating improving market participation.

Industry

Medical Devices

BUY participation
33.3%
Active BUY / eligible
2 / 6
30-Day BUY Count Change
+2

Sector signal summarizes BUY breadth conditions for the sector. It does not override this stock’s BUY, SELL, or PASS advisory.

Price Behavior

Downtrend
PRICE PATH

Downtrend

The stock has experienced a sustained decline in price over recent periods.

Smooth
PRICE STABILITY

Smooth

The stock has moved along a generally orderly path with only modest fluctuations.

Analysis of Past Performance

Type Stock
Historic Profit 18.45%
Avg. Invested days 44
Today’s Advisory Consider higher Upturn Star rating
Upturn Advisory Rating upturn star rating icon
Upturn Advisory Performance Upturn Advisory Performance icon 3.0
Stock Returns Performance Upturn Returns Performance icon 2.0
Upturn Profits based on simulation icon Profits based on simulation
Upturn last close icon Last Close 11/20/2026

Upturn Scorecard

Upturn Star Rating

★★★★★
SNN receives a 4-star rating, supported by solid unit economics, solid company fundamentals, and solid quantitative characteristics. The rating is constrained by weak price momentum.

Company Fundamentals

★★★★★
SNN has solid overall fundamentals (4 stars), with solid financial health, solid growth momentum, and moderate ownership. In FY2025 versus FY2024, strong earnings growth (+51.7%) and solid cash generation (FCF margin 13.8%) are partially offset by moderate revenue growth (+6.1%), very low insider ownership of 0.04%.

Financial Health Rating

★★★★★
SNN's financial health is supported by solid cash strength, including free-cash-flow generation (13.8% of revenue). Profitability is moderate (3 stars), which helps explain the 4-star overall score.

Growth Momentum Score

★★★★★
Earnings growth is SNN's strongest growth driver at +51.7% FY2025 versus FY2024 (strong, 5 stars). By comparison, free-cash-flow growth (+40.6%, strong) is also strong, while revenue growth (+6.1%, moderate) holds the profile back, so recent growth is not broad-based across the business.

Ownership

★★★★★
Institutional ownership is 8.7% (soft) and 503.8% of outstanding shares are publicly tradable (strong). Insider ownership is only 0.04%, which materially reduces the ownership score.

Top 5 Institutional Investors

River Road Asset Management, LLC 0.77%
The Goldman Sachs Group Inc 0.73%
Brandes Investment Partners & Co 0.51%
LMR Partners LLP 0.42%
Dimensional Fund Advisors, Inc. 0.42%

Unit Economics (Per $1K Revenue)

★★★★★
SNN generates approximately $683 of gross profit, $129 of operating income, and $138 of free cash flow for every $1,000 of revenue. Based on FY2025 results. Solid margins and solid cash conversion support the rating, although capital efficiency remains soft.

Economic Dimensions

★★★★★
Effective Tax Rate: 19.77%

Quantitative Style Profile

★★★★★
SNN has a high-quality, large-cap, liquid, relatively low-volatility profile. Weak momentum is the primary drawback.

Style Classification

Quality Focused

Value-OrientedQuality TiltLow VolatilityLarge / Mega Cap StabilityHighly Liquid / Institution-Friendly

How Company Makes Money

Business areaWhat it includesRetail investor read
OrthopaedicsKnee and hip replacement implants, trauma fixations, and surgical robotics equipment.Steady revenue generated from essential joint reconstruction surgeries performed globally.
Sports Medicine & ENTArthroscopic repair devices, soft tissue fixation tools, and visualization systems.Higher-margin consumable and device sales driven by sports injuries and outpatient arthroscopic surgeries.
Advanced Wound ManagementAdvanced wound dressings, negative pressure systems, and bio-active therapy products.Recurring institutional and home-care demand for specialized healing products addressing chronic wounds.

Analyzing Revenue: Products, Geography and Growth

Revenue by Products

Product revenue - Year on Year

Revenue by Geography

Geography revenue - Year on Year

Valuation

Trailing PE 20.29
Forward PE 11.53
Enterprise Value 15.70B
Price to Sales(TTM) 1.98
Enterprise Value 15.70B
Price to Sales(TTM) 1.98
Enterprise Value to Revenue 2.49
Enterprise Value to EBITDA 9.98
Shares Outstanding 418.11M
Shares Floating 2.11B
Shares Outstanding 418.11M
Shares Floating 2.11B
Percent Insiders 0.04
Percent Institutions 8.72

Financial Metrics

🧭 Investment Snapshot

Total Revenue (Scale)

Information icon Total money earned from selling products or services before any costs. It is needed to understand the scale of the business and its ability to generate income.

Net Income (Profit)

Information icon Final profit after all expenses, interest, and taxes are deducted. It is needed to determine the overall profitability available to shareholders.

Free Cash Flow (Cash Strength)

Information icon Cash remaining after operating activities and capital expenditures, showing cash available for growth. It is needed to evaluate the company’s ability to invest, pay dividends, or reduce debt.

📈 Growth & Strength

Operating Income (Core Profit)

Information icon Profit from core operations after deducting all operating expenses. It is needed to measure how efficiently the company runs its primary business activities.

EBITDA (Cash Earnings)

Information icon Earnings before interest, taxes, depreciation, and amortization, indicating operating cash potential. It is needed to compare operating performance across companies without accounting or financing differences.

Gross Profit (Unit Profitability)

Information icon Revenue minus cost of revenue, showing profit after direct production costs. It is needed to evaluate core business profitability before overhead expenses.

🛡️ Financial Safety

Cash (Liquidity Buffer)

Information icon Total cash and cash equivalents on hand. It is needed to evaluate immediate liquidity and financial flexibility.

Total Debt (Leverage Risk)

Information icon Total debt including both short-term and long-term components. It is needed to assess the company’s leverage and financial risk.

Net Working Capital (Short-Term Health)

Information icon Current assets minus current liabilities, indicating short-term liquidity strength. It is needed to assess whether the company can meet its short-term obligations.

🧱 Balance Sheet Strength

Stockholder Equity (Net Worth)

Information icon Total equity value held by shareholders. It is needed to understand the net worth of the company from the owners’ perspective.

Total Assets (Asset Base)

Information icon The full value of everything the company owns, including cash, inventory, equipment, and investments. It is needed to understand the resource base used to generate revenue.

Income Before Tax (Pre-Tax Earnings)

Information icon Income before provision for income taxes. It is needed to analyze profitability independent of tax structures.

⚙️ Cost & Drag Factors

Cost of Revenue (Production Cost)

Information icon Direct costs required to produce and deliver the products or services sold. It is needed to assess efficiency in production and service delivery.

Total Operating Expenses (Operating Cost)

Information icon Indirect costs of running the business such as salaries, marketing, and administration. It is needed to understand how much it costs to sustain ongoing business operations.

Income Tax Expense (Tax Drag)

Information icon Amount of taxes paid or payable to the government. It is needed to evaluate the impact of taxation on overall profitability.

Form CRS provides a relationship summary of our automated advisory services, flat subscription fees, and conflicts of interest. Form ADV Part 2A brochure contains complete details on services, billing, and disclosures. If any summary differs from our current regulatory filings, the filed Form ADV controls.